Show simple item record

dc.contributor.authorBlockman, M.
dc.contributor.authorCohen, K.
dc.contributor.authorDe Waal, R. 
dc.contributor.authorGray, A.
dc.contributor.authorKredo, T. 
dc.contributor.authorMaartens, G. 
dc.contributor.authorNel, J.
dc.contributor.authorParrish, A.
dc.contributor.authorRees, H.
dc.contributor.authorReubenson, G.
dc.date.accessioned2020-07-20T09:06:34Z
dc.date.available2020-07-20T09:06:34Z
dc.date.issued2020-05-11
dc.identifier.urihttps://infospace.mrc.ac.za/handle/11288/595268
dc.language.isoenen_US
dc.publisherSouth African National Department of Health en_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleAzithromycin for COVID‐19: evidence review of the clinical benefit and harmen_US
dc.typeArticleen_US
dc.contributor.department(Cochrane South Africa, South  African Medical Research Council, SA GRADE Network)en_US
dc.research.unitSouth African Cochrane Centreen_US
dc.date.epub2020-05-11


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States